Baxter International INC 10-Q quarterly reports

Baxter International reports Q2 2026 results with increased net sales and operating income, despite ongoing business transformation and supply chain challenges.

Baxter International Inc. reported a net loss of $15 million for the first quarter of 2026 as it navigates restructuring costs and regulatory challenges following the divestiture of its Kidney Care business.

Baxter International Inc. reported a net loss for the third quarter of 2025, impacted by significant special items including tax reserves and costs related to the Novum LVP recall, despite overall sales growth.

Baxter International reports mixed Q2 2025 results with increased sales and significant debt reduction, offset by margin compression and operational challenges.

Baxter International's Q1 2025 results show increased net income driven by the sale of its Kidney Care business, despite ongoing supply chain challenges and macroeconomic uncertainties.

Baxter International's Q3 results show a net income of $140 million, impacted by special items and the pending sale of its Kidney Care business, alongside challenges from Hurricane Helene.

Baxter International reported a net loss for the second quarter of 2024, impacted by a goodwill impairment and separation costs, while also seeing some revenue growth in certain segments.

Baxter International's first quarter results show a slight increase in sales but are impacted by separation costs and restructuring charges as the company plans to divest its Kidney Care business.